hzVSF-v13 + entecavir

hzVSF-v13 + entecavir is a **combination therapy** under investigation for the treatment of chronic hepatitis B. hzVSF-v13 is a humanized monoclonal antibody targeting vimentin and acts as a viral entry inhibitor, likely by suppressing vimentin-mediated endocytosis of hepatitis B virions[4]. Entecavir is a small molecule nucleoside analog that inhibits hepatitis B virus (HBV) DNA polymerase. The combination aims to provide enhanced antiviral efficacy: hzVSF-v13 interferes with the reinfection and maintenance of chronic HBV infection, while entecavir suppresses viral replication. Preclinical studies and Phase II trials are evaluating intravenous hzVSF-v13 in combination with daily oral entecavir[1][4]. The combination is anticipated to result in greater suppression of HBV (as measured by changes in HBsAg) in patients stably receiving entecavir[1].

Other names

hzVSF-v13hzVSF-v-13hzVSF-v 13entecavir